Scarica l'app Stockscreener
2.10
0.94%
-0.02
Dopo l'orario di chiusura:
2.07
-0.03
-1.43%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.12
Aprire:
$2.12
Volume 24 ore:
20,061
Relative Volume:
0.54
Capitalizzazione di mercato:
$24.31M
Reddito:
$3.35M
Utile/perdita netta:
$86,000
Rapporto P/E:
136.36
EPS:
0.0154
Flusso di cassa netto:
$2.67M
1 W Prestazione:
-6.25%
1M Prestazione:
+1.45%
6M Prestazione:
-8.70%
1 anno Prestazione:
+90.91%
Intervallo 1D:
$2.07
$2.17
Intervallo di 1 settimana:
$2.07
$2.23
Portata 52W:
$0.99
$2.95
Therapeuticsmd Inc Stock (TXMD) Company Profile
Nome
Therapeuticsmd Inc
Settore
Telefono
561-961-1900
Indirizzo
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
Compare TXMD vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TXMD
Therapeuticsmd Inc
|
2.10 | 24.54M | 3.35M | 86,000 | 2.67M | 0.0154 |
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 58.15B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.35 | 42.94B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.22 | 40.59B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
72.86 | 30.29B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
503.86 | 21.74B | 3.17B | 1.29B | 1.01B | 27.09 |
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-08-07 | Downgrade | Jefferies | Hold → Underperform |
| 2020-05-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-12-02 | Iniziato | Guggenheim | Buy |
| 2019-10-17 | Iniziato | H.C. Wainwright | Buy |
| 2019-04-30 | Ripresa | Noble Capital Markets | Outperform |
| 2018-06-15 | Iniziato | JP Morgan | Overweight |
| 2017-09-08 | Iniziato | Morgan Stanley | Equal-Weight |
| 2017-07-11 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2017-05-09 | Downgrade | Oppenheimer | Outperform → Perform |
| 2016-11-22 | Ripresa | Jefferies | Buy |
| 2016-11-22 | Iniziato | Oppenheimer | Outperform |
| 2016-11-07 | Ripresa | Guggenheim | Buy |
| 2016-04-04 | Iniziato | Goldman | Buy |
| 2015-12-08 | Reiterato | Jefferies | Buy |
| 2015-12-08 | Reiterato | Stifel | Buy |
| 2015-09-21 | Reiterato | Jefferies | Buy |
| 2015-06-09 | Iniziato | Guggenheim | Buy |
| 2014-07-08 | Iniziato | FBR Capital | Outperform |
| 2014-04-17 | Reiterato | Noble Financial | Buy |
| 2014-01-28 | Reiterato | Noble Financial | Buy |
Mostra tutto
Therapeuticsmd Inc Borsa (TXMD) Ultime notizie
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Therapeuticsmd Stock Price Forecast. Should You Buy TXMD? - StockInvest.us
TherapeuticsMD Inc. stock outperforms competitors despite losses on the day - MarketWatch
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
TXMD Q3 2023 Earnings: EPS Misses by 154.9% as Revenue Remains at ZeroEBITDA Margin Trends - vinanet.vn
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
TherapeuticsMD (TXMD) Holds Steady at $2.22 as Traders Eye Tight Trading RangeLong Setup Ideas - vinanet.vn
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
THERAPEUTICSMD STOCK : BIG PRICE RECOVERY | TXMD STOCK Moon (nkL8YZ0GKj) - Mshale
TherapeuticsMD (TXMD) Quarterly Figures: EPS Falls Short of Its Estimate under the Current Snapshot; Post-Earnings: The Stock Ends Up 0.49% in the Latest ReadingAnalyst Drop Coverage - vinanet.vn
TherapeuticsMD (TXMD) Range: Ends a Quiet Session at $2.06 in the Latest Reading; Levels: Traders Can Monitor the $1.96-$2.16 Range in the Available RecordHigh Volume Node - vinanet.vn
TherapeuticsMD (TXMD) Range: Moves 0.49% Down to $2.05; the Current Price Sits Inside the Supplied Technical Range for the Current SessionLiquidity Order Flow - vinanet.vn
TherapeuticsMD (TXMD) Results Review: The EPS Result Is Below Expectation for This Review; Post-Earnings: The Stock Records a 1.48% Increase at the CloseSegment Revenue Breakdown - vinanet.vn
TherapeuticsMD, Inc. Revenue Breakdown – NASDAQ:TXMD - TradingView
TherapeuticsMD(TXMD) Stock Options Chain | Quotes & News - Moomoo
TherapeuticsMD Company Profile & Introduction - Moomoo
TherapeuticsMD, Inc. Revenue Breakdown – DUS:29TA - TradingView
ACTU Stock Price and Chart — NASDAQ:ACTU - TradingView
TherapeuticsMD (TXMD) Holds Steady at $2.08 as Traders Eye Key Support and ResistanceBull Flag - vinanet.vn
TherapeuticsMD Q2 2026 License Revenue Drops 8.7% Year Over Year - clinicaltrialvanguard.com
TherapeuticsMD: Q2 Earnings Snapshot - AOL.com
TherapeuticsMD Q2 Net Income From Cont Ops US - Moomoo
TherapeuticsMD Q2 EPS drops 80% to $0.01 on sales slide - scanx.trade
Is TherapeuticsMD Inc (TXMD) Positioned for Growth After Q2 Earn - GuruFocus
TherapeuticsMD Q2 Results and Strategic Alternatives Review - TipRanks
TherapeuticsMD, Inc. Q2 2026: Revenue $869K, EPS $0.01— 10-Q Summary - TradingView
TherapeuticsMD Q2 license revenue falls; continues to evaluate strategic alternatives - TradingView
TherapeuticsMD Q2 2026 License Revenue Falls to $869000 - Quiver Quantitative
TherapeuticsMD | 10-Q: Q2 2026 Earnings Report - Moomoo
TherapeuticsMD Q2 2026 Earnings: License Revenue and Net Income Decline - TradingKey
TXMD: Q2 2026 saw lower net income and license revenue, with strategic alternatives under evaluation - TradingView
TherapeuticsMD (TXMD) posts Q2 2026 update and weighs strategic alternatives - Stock Titan
TherapeuticsMD to Recognize About $365K IMVEXXY Milestone in Q3 - Stock Titan
TherapeuticsMD, Inc. (29TA.SG) stock price, news, quote and history - Yahoo Finance Australia
TXMD Q3 2023 Earnings: Wider-Than-Expected Loss of -$0.13 Weighs on SharesEarnings Per Share - vinanet.vn
Baselake group (TXMD) discloses 6.8% beneficial stake in TherapeuticsMD common stock - Stock Titan
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
TherapeuticsMD, Inc. (29TA.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
TherapeuticsMD (TXMD) Holds Steady at $2.03 as Trading Range NarrowsVolume Rate Change - dars.gov.et
TXMD Q3 2023 Earnings: Wide EPS Miss Highlights Transition ChallengesEarnings Surprise Report - vinanet.vn
TXMD|TherapeuticsMD Inc|Price:2.090|Chg%:+0.060 - TradingKey
TherapeuticsMD Inc. (TXMD) Slips Further: Key Support Levels Under PressurePCR Spike - dars.gov.et
TherapeuticsMD, Inc. Revenue Breakdown – SWB:29TA - TradingView
TherapeuticsMD Inc (TXMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TherapeuticsMD Inc (TXMD) Cash Flow - TradingKey
TherapeuticsMD (TXMD) Holds Steady Near Key Support With Slight UptickProfitability Factor - dars.gov.et
TherapeuticsMD Inc (TXMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TherapeuticsMD Inc (TXMD) Valuation: PE, PB & Fair Value Analysis - TradingKey
TherapeuticsMD, Inc. Revenue Breakdown – MUN:29TA - TradingView
TherapeuticsMD Inc (TXMD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TherapeuticsMD Inc (TXMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Therapeuticsmd Inc Azioni (TXMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.56%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):